Bootstrap Bio and Manhattan Genomics, which were pursuing gene editing in human embryos to prevent serious disease, have shut down. Two companies that launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict. One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers in October that included a prominent fertility doctor, a data scientist who worked for de-extinction company Colossal Biosciences, and a scientist who pioneered a "three-parent" IVF technique. The other, California-based Bootstrap Bio, said it ceased operations in late 2025, as first reported by Mother Jones. Manhattan Genomics and Bootstrap Bio had ambitions to edit DNA in human embryos with the goal of preventing serious disease in babies.

Entrepreneurs say it's time to safety-test designer baby technology. A West Coast biotech entrepreneur says he's secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology. The new company, called Preventive, is being formed to research so-called "heritable genome editing," in which the DNA of embryos would be modified by correcting harmful mutations or installing beneficial genes. The goal would be to prevent disease. Preventive was founded by the gene-editing scientist Lucas Harrington, who described his plans yesterday in a blog post announcing the venture. Preventive, he said, will not rush to try out the technique but instead will dedicate itself "to rigorously researching whether heritable genome editing can be done safely and responsibly."